Back to top
more

Elevance Health, Inc. (ELV)

(Real Time Quote from BATS)

$419.13 USD

419.13
124,170

+1.27 (0.30%)

Updated Nov 5, 2024 10:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Why Is Elevance Health (ELV) Down 3.2% Since Last Earnings Report?

by Zacks Equity Research

Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills

by Zacks Equity Research

JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for JPMorgan Chase, Elevance Health & Vertex Pharmaceuticals

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Elevance Health, Inc. (ELV) and Vertex Pharmaceuticals Incorporated (VRTX).

Why Elevance Health (ELV) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Pediatrix (MD) Q4 Earnings miss on High Operating Expenses

by Zacks Equity Research

Pediatrix (MD) anticipates 2023 adjusted EBITDA to be within $235-$245 million.

Centene (CNC) Q4 Earnings Miss on High Costs, '23 Premium View Up

by Zacks Equity Research

Centene's (CNC) fourth-quarter results suffer from elevated medical expenses, partly offset by growing premium and service revenues.

Cigna (CI) Q4 Earnings Top on U.S. Commercial Unit, Dividend Up

by Zacks Equity Research

Cigna's (CI) fourth-quarter results reflect the strong contribution from the Evernorth segment. Management sanctions a 10% increase in the quarterly dividend.

Humana (HUM) Q4 Earnings Beat Mark, '23 EPS View Upbeat

by Zacks Equity Research

Humana's (HUM) fourth-quarter results benefit from solid premiums from its individual Medicare Advantage business and the sound performance of the two newly formed segments.

Sheraz Mian headshot

Q4 Earnings Season Scorecard and Analyst Reports for Apple, Meta & Mastercard

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Meta Platforms, Inc. (META) and Mastercard Incorporated (MA).

HCA Healthcare (HCA) Q4 Earnings Lag on High Costs, Hikes Dividend

by Zacks Equity Research

HCA Healthcare's (HCA) fourth-quarter results suffer a blow from added expenses incurred due to Hurricane Ian. Increased patient admissions partly offset the downside.

Elevance Health (ELV) Tops on Q4 Earnings, Hikes Dividend

by Zacks Equity Research

Elevance Health's (ELV) fourth-quarter earnings gain on solid premiums from its Medicaid business. Management approves a quarterly dividend hike of 16%.

Elevance Health (ELV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Elevance Health (ELV) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Elevance Health (ELV) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of 0.58% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Elevance Health (ELV) to Post Q4 Earnings: What to Expect

by Zacks Equity Research

Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums, Commercial & Specialty Business' sales and total expenses.

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

by Zacks Equity Research

Sector ETF report for IHF

The Zacks Analyst Blog Highlights Home Depot, Merck, Bank of America, Elevance Health and ResMed

by Zacks Equity Research

Home Depot, Merck, Bank of America, Elevance Health and ResMed are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Home Depot, Merck & Bank of America

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Merck & Co., Inc. (MRK) and Bank of America Corporation (BAC).

Why You Should Hold Elevance Health (ELV) in Your Portfolio

by Zacks Equity Research

Elevance Health (ELV) remains well-poised for growth due to a growing customer base within its Government and IngenioRx businesses coupled with solid cash-generating abilities.

UpHealth, Inc. (UPH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

UpHealth, Inc. (UPH) delivered earnings and revenue surprises of -525% and 18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ensign Group (ENSG) Rises 30% in 6 Months: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for improvement on growing revenues derived from catering to patients under Medicaid and Medicare programs. Solid cash flows are other tailwinds.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

ELV vs. PGNY: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. PGNY: Which Stock Is the Better Value Option?

Cigna (CI) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Cigna's (CI) stock price is increasing on the back of solid performances in the Evernorth and Cigna Healthcare businesses.